$2M Price Tag for Sickle Cell Gene Therapies Could Be Cost-Effective Under Certain Scenarios, Finds ICER Analysis
- Prices for incoming sickle cell disease gene therapies from Vertex Pharmaceuticals Inc (NASDAQ: VRTX)/CRISPR Therapeutics AG (NASDAQ: CRSP), dubbed exagamglogene autotemcel (exa-cel), and Bluebird bio Inc’s (NASDAQ: BLUE) lovotibeglogene autotemcel (lovo-cel) at $2 million could be cost-effective under some scenarios.
- Although “these gene therapies have an incremental cost-effectiveness that is above commonly cited thresholds from the health care system perspective.”
- The analysis comes from a U.S. drug pricing group, Institute for Clinical and Economic Review (ICER).
- Results showed that at the placeholder price of $2 million per treatment course for lovo-cel or exacel (to be paid upfront), 15.4% of people (N=385 people per year) could be treated over five years without crossing the ICER budget impact threshold of $777 million per year.
- Also Read: Newly Approved Drugs In US Command Over $200,000 On An Average.
- Similarly, 33.9%, 24.7%, and 19.4% could be treated with either lovo-cel or exa-cel without reaching the potential budget impact threshold at the three threshold prices (approximately $0.90 million, $1.24 million, and $1.58 million per treatment).
- “The draft cost-effectiveness findings were driven by the lifetime opportunity to improve health and reduce VOC-related and other SCD-related costs, and to improve productivity and reduce caregiver costs in the modified societal perspective,” ICER said.
- Bluebird Bio signaled a delay in its sickle cell disease drug application to the FDA in its Q4 earnings release.
- Vertex and CRISPR completed the rolling Biologics License Applications to the FDA for (exa-cel) for sickle cell disease and transfusion-dependent beta-thalassemia.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Biotech News Penny Stocks Health Care Small Cap Movers Trading Ideas General
